Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation

Real-life experience with first-line treatment with daratumumab, bortezomib, melphalan, and prednisone in patients with newly diagnosed multiple myeloma ineligible for autologous stem-cell transplantation

IntroductionThe regimen with daratumumab, bortezomib, melphalan, and prednisone (D-VMP) is one of the recommended treatments for newly diagnosed multiple myeloma (NDMM) non-transplant eligible due to the results described in the ALCYONE trial. However, real-life outcomes with this regimen are limite...

Full description

Bibliographic Details
Main Authors: Amalia Domingo-González, Rafael Alonso Fernández, Ana Jiménez, Teresa De Soto Álvarez, Ana Lerma-Verdejo, Virginia Pradillo, Gonzalo Benzo Callejo, Jose Sánchez-Pina, Elena Landete, Alberto Velasco-Valdazo, Marina Menéndez-Cuevas, Mónica María López Riñón, Andrés Ramírez-López, María-Jesús Blanchard, Elham Askari
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-09-01
Series:Frontiers in Hematology
Subjects:
newly diagnosed multiple myeloma
non-transplant candidates
daratumumab
bortezomib
melphalan and prednisone
real-life
Online Access:https://www.frontiersin.org/articles/10.3389/frhem.2024.1438233/full

Internet

https://www.frontiersin.org/articles/10.3389/frhem.2024.1438233/full

Similar Items